The patients in this group were supplemented with oral selenium at 0.1mg/kg doses twice daily for one month. After selenium supplementation period was completed, AC sampling as described above.

The patients in this group were supplemented with oral melatonin 0.5 mg/kg/day doses twice daily for one month. After supplementation was completed 0.1 cc sampling from AC.

Anterior Segment Ischemia (Diagnosis)

Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by selenium supplementation.

SELENIUM

Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by melatonin supplementation.

MELATONIN

Effects of Selenium and Melatonin on Ocular Ischemic Syndrome

Determine the Effects of Selenium and Melatonin on Ocular Ischemic Syndrome

The patients were supplemented with oral selenium at 0.1mg/kg doses twice daily for one month. After selenium supplementation period was completed, 0.1 cc samples were obtained from the anterior chamber (AC). And then determine AC Malondialdehyde (MDA) and Glutathione (GSH) levels.

The patients in this group were supplemented with oral melatonin 0.5 mg/kg/day doses twice daily for one month. After supplementation was completed 0.1 cc sampling from AC. And then determine AC Malondialdehyde (MDA) and Glutathione (GSH) levels.

Hande Telek

Ophthalmology, MD,Principal Investigator

Beytepe Murat Erdi Eker State Hospital

Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.

Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.

CYSTOID MACULAR EDEMA

Intravitreal injection of Ranibizumab as treatment for acute pseudophakic cystoid macular edema. Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.

Ranibizumab,

Intravitreal injection of Triamcinolone acetonide as treatment for acute pseudophakic cystoid macular edema. Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.

Triamcinolone acetonide

Soll Eye

Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide

To assess the safety of intravitreal R and T for the treatment of acute pseudophakic cystoid macular edema by evaluating:
Incidence and severity of ocular adverse events, as identified by eye examination
Incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs

Mean change in spectral domain OCT CMT from baseline (microns)

Mean change in ETDRS letters from baseline (letters)

Proportion of patients with 3 line or better ETDRS letter improvement (%)

Time to 3 line ETDRS letter improvement (days)

Genentech, Inc.

Diabetic Macular Edema

Danazol

Efficacy and Safety Study to Evaluate Two Doses of Oral DMI-5207 in Adult Subjects With Diabetic Macular Edema

A Randomized, Placebo-Controlled, Parallel Treatment Group, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral DMI-5207 in Adult Subjects With Diabetic Macular Edema

Change in Central Macular Thickness (CMT), measured by time-domain optical coherence tomography (OCT), from baseline to study endpoint at 12 weeks of study treatment compared to placebo

Change in Early Treatment Diabetic Retinopathy Study (ETDRS) best corrected visual acuity (BCVA) from baseline to study endpoint after 12 weeks of study treatment compared to placebo

Change in center subfield retinal volume as measured by OCT from baseline to study endpoint after 12 weeks of study treatment compared to placebo.

St. Michael's Hospital, Toronto

stratified equally to doxycycline monohydrate 50mg taken once daily for 24 months

stratified equally to placebo taken once daily for 24 months

stratified equally to placebo taken once daily for 24 months
placebo: placebo taken once daily for 24 months

Placebo

stratified equally to doxycycline monohydrate 50mg taken once daily for 24 months
doxycycline monohydrate: 50mg once daily for 24 months

Doxycycline Monohydrate

Total

Sex: Female, Male

Race (NIH/OMB)

Region of Enrollment

Change in dark adaptation is measured as dark adaptation time at baseline measured in minutes minus dark adaptation time measured at 24 months

Change in Dark Adaptation, Rod Intercept

Change in photopic visual fields between baseline and 24 months

Change in Photopic Visual Field

Change in Frequency Doubling Perimetry (FDP) from baseline, shown as mean and foveal (center of retina) scores

Change in Frequency Doubling Perimetry (FDP)

Change in ETDRS visual acuity letter score from baseline. ETDRS is measured on a scale of 0 to 70 where 0 means inability to see anything on the chart and 70 is normal (20/20) acuity.

Change in Early Treatment Diabetic Retinopathy Study (ETDRS)

Change in central subfield thickness from baseline

Change in Central Subfield Thickness

Change in Macular Volume

Change in Central Retinal Artery Equivalent (CRAE) diameter from baseline

Change in Central Retinal Artery Equivalent (CRAE) Diameter

Change in Central Retinal Vein Equivalent (CRVE) diameter from baseline

Change in Central Retinal Vein Equivalent (CRVE) Diameter

Change in arteriovenous ratio diameter from baseline

Change in Arteriovenous Ratio Diameter

Overall Study

Dr. Thomas W. Gardner